Summary

  • In IPG Photonics’ signed agreement to buy Lumibird Medical, the seller’s aggregate liability for Business Warranty Claims is capped at €1. For those claims above €1, IPG’s sole recovery is the W&I insurance policy.
  • That sentence does not cap every seller obligation at €1 or guarantee insurance proceeds. Fundamental Warranties, Specific Indemnities, covenants, fraud and price adjustments have separate rules, while IPG bears the policy’s retention, excess or deductible.

One euro is barely a price. In this agreement it is a border.

IPG Photonics signed the share purchase agreement for Lumibird Medical on 8 September, after Lumibird completed its French works-council process and exercised the put option agreed in July. The acquisition materials lead with a €300 million cash-free, debt-free base value and up to €50 million of additional cash. Deep in the executed contract, however, a smaller number decides who absorbs a particular kind of post-closing surprise.

Lumibird’s aggregate liability for claims under the ordinary Business Warranties “shall in no event exceed” €1. IPG agrees that recovery above that amount for those warranties lies solely under a warranty-and-indemnity insurance policy. The seller gave the Business Warranties for the sole purpose of enabling the buyer to obtain that policy.

This does not make the warranties decorative. They define the representations against which the insurer can assess a covered breach. But it changes the recovery path. For ordinary business matters, the first important question after a loss is not simply whether Lumibird’s representation was wrong. It is whether the loss enters the policy, survives its retention and exclusions, meets its procedural rules and remains within its limit.

The policy itself is not filed. Its insurer, premium, retention, exclusions, limit and detailed claims protocol are therefore absent from the public evidence. The SPA says enough to show where risk has moved, but not enough to measure how much protection arrived there.

The cap survives a failed policy

The cleanest way to understand the contract is to imagine a Business Warranty breach that causes IPG a direct loss after closing. Lumibird’s seller liability for that class of claim reaches only €1 in aggregate. For the portion above €1, IPG must look to the W&I policy.

The agreement then closes an obvious escape route. The monetary cap continues to apply even if the insurer does not pay, the policy is invalid, expired, terminated or defective, or an insurer or underwriter becomes insolvent. IPG also accepts any excess, retention or deductible retained under the policy and cannot pass that amount back to Lumibird through a Business Warranty Claim.

That is genuine risk transfer, but it is not complete risk removal. A policy can transfer covered loss to an insurer. It cannot make exclusions disappear, turn a deductible into seller money or supply evidence that was never preserved. The contract makes IPG the residual owner of several gaps before anyone knows whether a claim will occur.

The closing mechanics recognise this dependence. IPG must deliver an executed copy of the W&I policy, including its subrogation waiver, together with evidence that it is effective and in force. Insurance is therefore part of the completion architecture, not a later procurement convenience. Still, proof that a policy exists is different from proof that a future fact pattern is covered.

€1 does not describe the whole seller exposure

The headline becomes misleading if “Business Warranties” is shortened to “all warranties” or “all liabilities”. The SPA explicitly separates several channels.

Fundamental Warranties are not Business Warranties. The filing says Lumibird indemnifies IPG for losses relating to those fundamental representations to the extent they exceed available W&I coverage. The agreement gives Fundamental Warranty Claims a five-year notice period and places aggregate seller claims, including fundamental claims, under a cap equal to the Purchase Price rather than €1.

Specific Indemnities are another category. They are standalone obligations, do not require a warranty breach and have their own caps and deadlines in Schedule 9.2.1. The public exhibit does not reveal enough of that schedule to total the protection. Fraud or wilful misconduct is not protected by the cited limitations. Covenants, completion deliveries, the purchase-price adjustment and the three-year non-compete also do not become Business Warranty Claims merely because they share the same document.

The useful mental model is a waterfall with labelled channels. Business Warranty Claims flow toward the policy above €1. Fundamental claims can reach the seller under a different cap. Specific indemnities follow their schedules. Fraud sits outside the limitation. Price mechanics move through the completion statement and independent-expert process. Combining them into one “insured deal” number would hide the contract’s operating design.

Diligence and final disclosure carry economic weight

The Business Warranties are qualified by matters Fairly Disclosed in the agreed information. If a matter was fairly disclosed, it cannot support a Business Warranty Claim against the seller. Lumibird may update the disclosed information no later than two business days before completion.

That short window is not administrative trivia. A final disclosure can shift an issue from an allegedly unknown breach into a known matter that the buyer accepts, renegotiates or addresses before closing. Because ordinary seller recourse is nearly absent, IPG’s review of those updates is part of the price of protection. The diligence archive must show what was known, when it was known and which contract or policy response followed.

The claim filters matter as much as the representations. A contingent liability does not create seller liability until it becomes actual, due and payable. A third-party claim must be resolved by settlement or enforceable decision under the cited clause. Losses are limited to direct, actual and foreseeable amounts; the definition excludes lost opportunity, lost profit, reputational, punitive, indirect and unforeseeable loss.

There are also clocks. Fundamental Warranty notices run for five years from completion. Tax and Employment Warranty notices generally run for four years, or longer where the statutory period requires the specified extension. Other claims generally run for two years unless a longer commitment applies. Individual or substantially identical claims below 0.15% of the Estimated Purchase Price do not create seller liability under the threshold clause.

None of those provisions proves that the insurer uses precisely the same tests. The unfiled policy controls insurance recovery. That is why public analysis cannot turn the SPA’s claim language into a coverage opinion.

The price has a different reconciliation

The €300 million figure is a Base Value. The executed formula subtracts Completion Net Indebtedness and adds the Completion Working Capital Adjustment. At least ten business days before completion, Lumibird must provide an estimated statement, including the expected price, cash by group company and certain lender and intercompany balances.

Payment may be routed partly to lenders or used to settle seller facilities and treasury agreements. After closing, IPG has 60 business days to deliver a draft completion statement. Lumibird then has 30 business days to object. Unresolved items can go to an independent expert, whose determination is generally final and binding except for fraud or manifest error.

Thus €300 million is not necessarily the final seller cheque. Nor is the €50 million earn-out a promised outflow. The additional purchase price is capped at €50 million less specified 2026 and 2027 bonus costs, while the detailed formula sits in Schedule 3.5. Any payment made under the indemnity clause is treated as a reduction of Purchase Price for tax, accounting and reporting purposes. That classification must not be confused with cash collected before a claim is resolved.

IPG says it expects to use cash on hand. At 30 June it reported $399.225 million in cash and equivalents, $472.094 million of short-term investments and $225.882 million of unused credit lines and overdraft facilities. It also generated $32.3 million of operating cash in the first half while spending $37.0 million on capital expenditure.

Those figures establish capacity, not a ring-fenced funding receipt. The price is denominated in euros, the final completion payment will be adjusted, and part of the liquidity portfolio sits in securities rather than cash equivalents. A future cash-flow statement must show what was liquidated, transferred or borrowed; the June balance cannot do that in advance.

The valuation denominator changes with the accounting frame

Lumibird Medical reported €112.2 million of 2025 IFRS revenue and €24.1 million of IFRS EBITDA, a 21.5% margin. IPG’s presentation then removes €0.6 million of IFRS 16 lease charges, €4.2 million of capitalised R&D and €0.4 million of other items to reach €18.9 million of adjusted EBITDA and a 16.8% margin.

The advertised 15.9 times multiple divides the €300 million price by that lower adjusted EBITDA, not by the reported €24.1 million. Both measures can be useful, but they answer different questions. The same discipline applies to IPG’s claims that the acquisition will add margin, EBITDA and adjusted EPS: those are forecasts made before regulatory clearance, closing, purchase accounting and integration.

The warranty structure sits beneath those forecasts. If an inherited issue disrupts a product line, regulatory approval, distributor relationship or facility, the operational loss may be much larger than the amount recoverable under a Business Warranty. The practical protection depends on which clause, policy term and loss definition accepts the event.